UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil

Table 4 Association between UDP-glucuronosyltransferase1A1 genotypes and pharmacokinetics parameters

Genotype	AUC CPT-11		AUC SN-38		AUC SN-38G		AUC SN-38G/AUC SN-38 ratio
	Median	P value	Median	P value	Median	P value	Median	P value
UGT1A1*28
TA6/6	5554.57	0.1631	176.40	0.1491	582.14	0.9881	3.178	0.1581
TA6/7	6919.11		213.25		591.86		3.330
TA7/7	9049.03		390.00		584.63		1.488
UGT1A1*6
G/G	5811.73	0.9532	189.62	0.3202	529.96	0.2342	2.924	0.5912
G/A	6582.17		231.50		679.17		3.759
UGT1A1*28+*6
TA6/6 + G/G	5297.41	0.2821	169.62	0.0841	529.96	0.3861	2.924	0.1881
TA6/7 + G/G, TA6/6 + G/A	6649.50		217.87		679.17		3.680
TA7/7 + G/G TA6/7+ G/A	6213.46		297.89		584.63		1.488
UGT1A1*28
TA6/6, TA6/7	6030.13	0.8842	191.92	0.0672	582.14	1.0002	3.177	0.0572
TA7/7	9049.03		390.00		584.63		1.488
UGT1A1*28+*6
TA6/6 + G/G, TA6/7 + G/G, TA6/6 + G/A	6030.13	0.7482	183.37	0.0612	582.14	0.9152	3.177	0.0782
TA7/7 + G/G, TA6/7 + G/A	6213.46		297.89		584.63		1.488

¹Kruskal-Wallis test;

²Mann-Whitney U test. 34 patients were assessable for pharmacokinetics parameters. CPT-11: Irinotecan; UGT1A1: UDP-glucuronosyltransferase1A1; AUC: Area under concentration curve.